Biotechnology

Biocytogen Subsidiary Eucure Biopharma Reports First Patient Enrolled in anti-CTLA4 Phase I Trial in China

BOSTON and BEIJING, Jan. 26, 2021 /PRNewswire/ -- Eucure Biopharma, a subsidiary of Biocytogen, announced the first patient enrollment for a Phase I clinical trial inChina to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of its anti-CTLA4 monoclonal antibody (YH001)...

2021-01-26 23:45 1535

Precision Medicine Leader Caprion-HistoGeneX Rebrands as CellCarta

MONTREAL, Jan. 26, 2021 /PRNewswire/ -- Caprion-HistoGeneX, a leading global provider of specialized precision medicine laboratory services to the biopharmaceutical industry, is pleased to announce its new corporate name, CellCarta, and brand identity.

2021-01-26 21:23 4846

Samsung Biologics Reports 66% Increase in 2020 Revenue Achieving "1 Trillion Won" Target Sales

INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) reported its fourth quarter and full-year 2020 financial results indicating strong business performance, benefitting from increased sales across all plants and significant business agility and operating excelle...

2021-01-26 15:00 6702

BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine

MAINZ, Germany and SHANGHAI, China, 25 Jan. 2021 /PRNewswire/ -- BioNTech SE  (Nasdaq: BNTX, "BioNTech" or "the Company") andShanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "Group"; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health Bureau of ...

2021-01-26 01:18 6375

China Biologic Announces Extraordinary General Meeting of Shareholders

BEIJING, Jan. 25, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that it has called an extraordinary general meeting of shareholders (the "EGM...

2021-01-25 21:44 9704

BioVaxys Announces Initiation Of Cancer Vaccine EU Clinical Program, Completion Of BVX-0320 Preclinical Program

VANCOUVER, BC, Jan. 25, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys" or "Company") is pleased to provide a corporate update on recent advancements of its vaccine platforms, and viral diagnostic and corporate objectives for 2021. BioVaxys is ple...

2021-01-25 21:00 3731

KPMG announces Top 50 Biotech Enterprises in the Greater Bay Area

HONG KONG, Jan. 25, 2021 /PRNewswire/ -- The third annual Guangdong-Hong Kong-Macao Greater Bay Area ("GBA") Leading Biotech 50 Awards Ceremony and Biotech Innovation and Development Summit ("the Summit") was recently held in Nansha,Guangzhou, where the list of the top 50 innovative biotech compa...

2021-01-25 16:35 2776

Antengene Announces Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

SHANGHAI and HONG KONG, Jan. 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncol...

2021-01-25 08:20 3253

HistoIndex Explores the Clinical Utility of Stain-free AI Digital Pathology Platform in 388 Patients with Triple-Negative Breast Cancer (TNBC)

SINGAPORE, Jan. 25, 2021 /PRNewswire/ -- HistoIndex 's stain-free AI digital pathology platform, incorporating Second Harmonic Generation (SHG), holds promise as a quantitative tool in the assessment of morphological and architectural changes in collagen fibers w...

2021-01-25 06:00 2157

Happiness Biotech Announces Financial Results for the Six Months Ended September 30, 2020 and Provides Guidance For the Whole Fiscal Year Ending March 31, 2021

NANPING, China, Jan. 22, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, today announced its unaudited financial results for the six months endedSeptember 30, 2020 and provided the guida...

2021-01-22 21:00 11521

Nanoform's Clinical Study Indicates Positive Interim Results

HELSINKI, Jan. 22, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, today announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful. Nanoform has received...

2021-01-22 15:43 1780

Menarini Receives European Commission Approval of ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

- ELZONRIS is the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, inEurope - Approval is based on the results of the largest prospective clinical trial ever conducted in patients with treatment-naïve or previously-treated BPDCN FLORENCE, Italy, Ja...

2021-01-22 02:25 4461

LumiraDx Receives SARS-CoV-2 Antigen Test Authorization in Japan and Brazil; Italy Recommends Expansion of Microfluidic Antigen Testing

LONDON, Jan. 21, 2021 /PRNewswire/ -- LumiraDx, the next-generation point-of-care diagnostic testing company, announced today multinational approvals of its SARS-CoV-2 Antigen Test. With approvals inJapan and Brazil, the fast, accurate LumiraDx SARS-CoV-2 Antigen Test is now available to patie...

2021-01-21 16:00 2242

Northway Biotech Opens New Biopharmaceutical Manufacturing Facility in Greater Boston Area

WALTHAM, Mass., Jan. 21, 2021 /PRNewswire/ -- Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art, cGMP manufacturing site inEurope, announced at the virtual grand opening ceremony o...

2021-01-21 12:35 1597

Innodem Neurosciences Receives 6 Million US Dollars of Financing From Morningside Group

MONTREAL, Jan. 20, 2021 /PRNewswire/ -- Innodem Neurosciences, a Montreal-based company, has closed a Series A financing round led byMorningside Ventures to support the development and commercialization of its proprietary, patented, digital biomarking technology of neurodegenerative diseases such...

2021-01-20 12:00 2812

CytoSorbents Announces Approval of CytoSorb® in Korea in Collaboration with Partner Fresenius Medical Care

CytoSorb now commercially available in Korea – one of the leading economies in Asia - to treat cytokine storm and other illnesses in critically-ill and cardiac surgery patients MONMOUTH JUNCTION, N.J., Jan. 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunot...

2021-01-19 20:08 6659

InDevR Launches VaxArray Measles and Rubella Kit for Improved Vaccine Antigen Characterization

BOULDER, Colorado, Jan. 19, 2021 /PRNewswire/ -- InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its VaxArray® Measles and Rubella (MR) antigen qu...

2021-01-19 16:00 1425

Neurophth and AAVnerGene Enter Strategic AAV Capsids Partnership for Next-Generation Ophthalmic Gene Therapy

WUHAN, China and NEWARK, DE., Jan. 19, 2021 /PRNewswire/ -- Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy company (hereafter Neurophth), and AAVnerGene Inc., a specializing AAV technology company, today announced a strategic partnership to provide ...

2021-01-19 14:05 1846

Innovent Announces an Out-license Agreement with PT Etana Biotechnologies Indonesia to Launch BYVASDA® (Bevacizumab Biosimilar) in Indonesia

SAN FRANCISCO and SUZHOU, China, Jan. 19, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-01-19 08:00 8410

Cure Genetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy

SUZHOU, China, Jan. 18, 2021 /PRNewswire/ -- Cure Genetics announced a collaboration with Boehringer Ingelheim to develop novel Adeno-Associated Virus (AAV) vectorsleveraging Cure Genetics' proprietary VELPTM platform to develop next-generation gene therapies. This new collaboration combines Boeh...

2021-01-18 22:00 2372
1 ... 333334335336337338339 ... 341

Week's Top Stories